

Supplementary Information

Pharmacometabolomics for predicting variable busulfan exposure in paediatric haematopoietic stem cell transplantation patients

Bora Kim^{1,*}, Ji Won Lee^{2,*,#}, Kyung Taek Hong², Kyung-Sang Yu¹, In-Jin Jang¹, Kyung Duk Park², Hee Young Shin², Hyo Seop Ahn², Joo-Youn Cho¹, and Hyoung Jin Kang²

¹Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Korea; ²Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine and Hospital, Seoul, Korea.

*These authors equally contributed to this work.

#Current affiliation: Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine




Corresponding Authors:

Hyoungh Jin Kang, E-mail: kanghj@snu.ac.kr Phone: (82)2-2072-3304, Fax: (82)2-743-3455



Joo-Youn Cho, E-mail: joocho@snu.ac.kr Phone: (82)2-2072-3625, Fax: (82)2-743-3455

Supplementary Figures


Supplementary Figure S1. **(A)** Deferoxamine structure and its mass fragmentation. **(B)** MS/MS spectra of urinary deferoxamine (upper) and authentic deferoxamine (lower). The fragments and relative intensities of 16 urinary metabolites were compared with the fragmentation pattern of authentic deferoxamine.

A**B**

Supplementary Figure S2. The fragments of urinary C9:1 carnitine was compared with authentic C8:0 carnitine. MS/MS spectra and each structure of C9:1 carnitine and C8:0 carnitine.



Supplementary Figure S3. The fragments of urinary C12:1-OH carnitine was compared with authentic C10:0 carnitine. MS/MS spectra and each structure of C12:1-OH carnitine and C10:0 carnitine.



Supplementary Figure S4. Phenylacetylglutamine structure and MS/MS spectra of urinary PAGN, [M-H]⁻ adduct, [2M+Na-2H]⁻ adduct, and authentic PAGN.

